The quickly developing field of personalized medicine is changing diagnostics, treatment and the interplay between the two. This creates challenges for the Food and Drug Administration, which regulates diagnostic tests and drugs quite differently. Could it also mean a change in the economic balance of power between drug and diagnostics companies? I recently covered a Wharton School discussion on the topic for Penn’s LDI Health Economist. — Dinah Wisenberg Brin